Reuters logo
BRIEF-Richter signs deal with DM Bio for biosimilar cancer medicine
October 19, 2016 / 6:15 AM / a year ago

BRIEF-Richter signs deal with DM Bio for biosimilar cancer medicine

Oct 19 (Reuters) - Richter Gedeon Nyrt

* Has signed an agreement with DM Bio for development and sale of biosimilar medicine trastuzumab.

* Trastuzumab designed for the treatment of an aggressive form of breast cancer as well as a form of metastatic gastric cancer.

* Richter receives exclusive distribution rights for Europe, CIS region and Latin American countries, obtains pilot technology for further development.

* Richter to make upfront payment upon signature of the contract and further milestone payments depending on the progress of the technology transfer and clinical programme.

* Further sales related royalties will be payable to DM Bio after launch of the product. Further company coverage: (Reporting by Gergely Szakacs, editing by Louise Heavens)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below